Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Activation of the Receptor PPARg/RXR as a Possible Treatment for Alzheimer's Disease. Role of Genistein.

NCT01982578 is registered in ClinicalTrials.gov with Fundación para la Investigación del Hospital Clínico de Valencia as lead sponsor.

NCT NCT01982578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01982578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Activation of the Receptor PPARg/RXR as a Possible Treatment for Alzheimer's Disease. Role of Genistein.
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Phase
Not applicable
Overall status
Completed
Start date
September 1, 2017
Completion date
December 31, 2020
Enrollment
27 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease